Latest News and Press Releases

NT219 is a first-in-class drug candidate with high affinity and selectivity to its target proteinsData show that even a short exposure of cancerous cells to NT219 was sufficient to trigger...

- Kitov to receive $3.5M milestone payments and 40% - 60% of net profit on sales of Consensi ™- Coeptis to cover all CMC, sales, and marketing expenses TEL AVIV, Israel, Jan. 03, 2019 (GLOBE...

Simcha Rock to Retire as CFO and Remain on Kitov’s Board of Directors TEL AVIV, Israel, Oct. 11, 2018 (GLOBE NEWSWIRE) --  Kitov Pharma (NASDAQ/TASE: KTOV), an innovative biopharmaceutical...

Treatment with NT219 in combination with Keytruda® or Erbitux® converted non-responding tumors to responders TEL AVIV, Israel, Sept. 26, 2018 (GLOBE NEWSWIRE) --  Kitov Pharma (NASDAQ/TASE:...

Tel Aviv, Israel, Sept. 18, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that, following a filing by Kitov’s Chairman of...

Tel Aviv, Israel, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today provided a corporate update and reported financial results...

Tel Aviv, Israel, July 30, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (Nasdaq: KTOV; TASE: KTOV.TA), an innovative biopharmaceutical company, today announced that it has entered into a Stipulation...

Tel Aviv, Israel, June 27, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (Nasdaq: KTOV; TASE: KTOV), an innovative biopharmaceutical company, today announced that it will host a business update...

Results in PDX model of pancreatic cancer supports planned IND for NT219 Completes acquisition of substantially all minority shares of TyrNovo, June 15, 2018 TEL AVIV, Israel, June 15, 2018 ...

TEL-AVIV, Israel, June 01, 2018 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (NASDAQ/TASE: KTOV), an innovative biopharmaceutical company, today announced that it has entered into definitive agreements...